The GLOBE score is an internationally relevant and validated risk assessment tool, able to accurately stratify PBC patients to high and low risk.

Age, yearsat initiation of UDCA therapy

Total bilirubin level, µmol/L or mg/dlafter one year of UDCA therapy

Upper limit of normal:

Alkaline phosphatase level, U/Lafter one year of UDCA therapy

Upper limit of normal:

Albumin, g/Lafter one year of UDCA therapy

Lower limit of normal:

Platelets, x 109/Lafter one year of UDCA therapy

Interpretation of the GLOBE score:

Patients with a GLOBE score corresponding with an estimated transplant-free survival comparable with an age- and sex-matched population are at low risk for future adverse events and patients with a GLOBE score corresponding with a transplant-free survival that significantly deviates from an age- and sex-matched population may benefit from new therapies

Data of an age- and sex-matched population, a population with a life-expectancy comparable with that of other countries participating in the Global PBC Study Group, were retrieved from a Dutch registry (Statistics Netherlands, www.cbs.nl).